Analysts expect the global healthcare giant to post earnings of 91 cents per share on revenue of $9.78 billion.
Last year, Merck reported earnings of 86 cents per share on revenue of $9.79 billion.
The company announced today that it signed a new partnership with molecular diagnostic provider Amoy Diagnostics to develop a liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer, TheFly reports.
The technology will be made available in China in 2017 and can be used to support specific gene-mutation analysis, according to TheFly.
Additionally, Merck said yesterday that its experimental Ebola vaccine V920 has received accelerated review status in the U.S. and E.U. The FDA tagged the drug as a Breakthrough Therapy.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate MERCK & CO as a Buy with a ratings score of B. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
You can view the full analysis from the report here: MRK